Updated: Eli Lilly's tirzepatide breaks into obesity market with FDA approval
Eli Lilly’s tirzepatide is officially entering the market for chronic weight management.
The drugmaker said Wednesday that the GIP/GLP-1 receptor agonist …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
